Skip to main content

Advertisement

Log in

111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging

  • Guidelines
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

This document provides general information about somatostatin receptor scintigraphy with 111In-pentetreotide. This guideline should not be regarded as the only approach to visualise tumours expressing somatostatin receptors or as exclusive of other nuclear medicine procedures useful to obtain comparable results. The aim of this guideline is to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of 111In-pentetreotide scintigraphy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, et al. Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med 2001;42(7):1134–8.

    CAS  PubMed  Google Scholar 

  2. Kwekkeboom DJ, Krenning EP, Scheidhauer K, Lewington V, Lebtahi R, Grossman A, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology 2009;90(2):184–9.

    Article  CAS  PubMed  Google Scholar 

  3. Lamberts SW, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 1990;323(18):1246–9.

    Article  CAS  PubMed  Google Scholar 

  4. Seregni E, Chiti A, Bombardieri E. Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results. Eur J Nucl Med 1998;25(6):639–58.

    Article  CAS  PubMed  Google Scholar 

  5. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20(8):716–31.

    Article  CAS  PubMed  Google Scholar 

  6. Jamar F, Fiasse R, Leners N, Pauwels S. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med 1995;36(4):542–9.

    CAS  PubMed  Google Scholar 

  7. Olsen JO, Pozderac RV, Hinkle G, Hill T, O’Dorisio TM, Schirmer WJ, et al. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Semin Nucl Med 1995;25(3):251–61.

    Article  CAS  PubMed  Google Scholar 

  8. Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, et al. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol 2008;26(6):963–70.

    Article  PubMed  Google Scholar 

  9. Wong KK, Cahill JM, Frey KA, Avram AM. Incremental value of 111-In pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors. Acad Radiol 2010;17:291–7.

    Article  PubMed  Google Scholar 

  10. Steffen IG, Mehl S, Heuck F, Elgeti F, Furth C, Amthauer H, et al. Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: is there an impact on sensitivity? Clin Nucl Med 2009;34(12):869–73.

    Article  PubMed  Google Scholar 

  11. Krausz Y, Keidar Z, Kogan I, Even-Sapir E, Bar-Shalom R, Engel A, et al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) 2003;59(5):565–73.

    Article  Google Scholar 

  12. Schillaci O, Scopinaro F, Angeletti S, Tavolaro R, Danieli R, Annibale B, et al. SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors. J Nucl Med 1996;37(9):1452–6.

    CAS  PubMed  Google Scholar 

  13. Warner RR, O’dorisio TM. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview. Semin Nucl Med 2002;32(2):79–83.

    Article  PubMed  Google Scholar 

  14. Westlin JE, Janson ET, Arnberg H, Ahlström H, Oberg K, Nilsson S. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide. Acta Oncol 1993;32(7–8):783–6.

    Article  CAS  PubMed  Google Scholar 

  15. Schmidt M, Scheidhauer K, Luyken C, Voth E, Hildebrandt G, Klug N, et al. Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med 1998;25(7):675–86.

    Article  CAS  PubMed  Google Scholar 

  16. Pichler R, Pichler J, Mustafa H, Nussbaumer K, Zaunmüller T, Topakian R. Somatostatin-receptor positive brain stem glioma visualized by octreoscan. Neuro Endocrinol Lett 2007;28(3):250–1.

    CAS  PubMed  Google Scholar 

  17. Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Kooij PP, Lamberts SW. Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med 1993;20(4):283–92.

    Article  CAS  PubMed  Google Scholar 

  18. Kälkner KM, Janson ET, Nilsson S, Carlsson S, Oberg K, Westlin JE. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers. Cancer Res 1995;55(23 Suppl):5801s–4.

    PubMed  Google Scholar 

  19. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996;125(1):26–34.

    CAS  PubMed  Google Scholar 

  20. Kwekkeboom DJ, Krenning EP, Kho GS, Breeman WA, Van Hagen PM. Somatostatin receptor imaging in patients with sarcoidosis. Eur J Nucl Med 1998;25(9):1284–92.

    Article  CAS  PubMed  Google Scholar 

  21. Kwekkeboom DJ, Krenning EP. Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview. Eur Radiol 1997;7(7):1103–9.

    Article  CAS  PubMed  Google Scholar 

  22. Briganti V, Sestini R, Orlando C, Bernini G, La Cava G, Tamburini A, et al. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors. Clin Cancer Res 1997;3(12 Pt 1):2385–91.

    CAS  PubMed  Google Scholar 

  23. Chiti A, Briganti V, Fanti S, Monetti N, Masi R, Bombardieri E. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours. Q J Nucl Med 2000;44(1):42–9.

    CAS  PubMed  Google Scholar 

  24. Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M, et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med 1998;25(10):1396–403.

    Article  CAS  PubMed  Google Scholar 

  25. Gibril F, Reynolds JC, Chen CC, Yu F, Goebel SU, Serrano J, et al. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med 1999;40(4):539–53.

    CAS  PubMed  Google Scholar 

  26. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997;38(6):853–8.

    CAS  PubMed  Google Scholar 

  27. Lebtahi R, Cadiot G, Delahaye N, Genin R, Daou D, Peker MC, et al. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy. J Nucl Med 1999;40(10):1602–8.

    CAS  PubMed  Google Scholar 

  28. Khanna G, O’Dorisio MS, Menda Y, Glasier C, Deyoung B, Smith BJ, et al. Somatostatin receptor scintigraphy in surveillance of pediatric brain malignancies. Pediatr Blood Cancer 2008;50(3):561–6.

    Article  PubMed  Google Scholar 

  29. Kropp J, Hofmann M, Bihl H. Comparison of MIBG and pentetreotide scintigraphy in children with neuroblastoma. Is the expression of somatostatin receptors a prognostic factor? Anticancer Res 1997;17(3B):1583–8.

    CAS  PubMed  Google Scholar 

  30. ICRP Publication 80. Radiation dose to patients from radiopharmaceuticals. Ann ICRP 1998;28:3. Oxford: Pergamon.

    Google Scholar 

  31. ICRP Publication 62. Radiological protection in biomedical research. Ann ICRP 1991;22:3. Oxford: Pergamon.

    Google Scholar 

  32. ICRP Publication 53. Radiation dose to patients from radiopharmaceuticals. Ann ICRP 1987;18:1–4. Oxford: Pergamon.

    Google Scholar 

  33. Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007. Ann ICRP 2008;38(1–2):1–197.

    Google Scholar 

  34. EANM Physics Committee, Busemann Sokole E, Płachcínska A, Britten A, EANM Working Group on Nuclear Medicine Instrumentation Quality Control, Lyra Georgosopoulou M, et al. Routine quality control recommendations for nuclear medicine instrumentation. Eur J Nucl Med Mol Imaging 2010;37:662–71.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Arturo Chiti.

Additional information

This guideline summarises the views of the Oncology Committee of the EANM and reflects recommendations for which the EANM cannot be held responsible. The recommendations should be taken in the context of good practice of nuclear medicine and do not substitute for national and international legal or regulatory provisions.

The guidelines have been reviewed by the EANM Dosimetry Committee, the EANM Physics Committee and the EANM Radiopharmacy Committee.

The guidelines have been brought to the attention of the National Societies of Nuclear Medicine.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bombardieri, E., Ambrosini, V., Aktolun, C. et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 37, 1441–1448 (2010). https://doi.org/10.1007/s00259-010-1473-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-010-1473-6

Keywords

Navigation